Volare opens its first industrial insect protein factory in Pori, on schedule and on budget
Volare completed its first industrial insect protein factory in Pori within a €15m capex budget and raised €7.1m through Springvest.
Volare, a Finnish insect protein company founded in 2021 on technology out of the VTT Technical Research Centre of Finland, has completed Volare 01, its first industrial-scale factory, in Pori. Tech.eu reported the completion on 26 October 2026. The 10,000 square metre plant is designed for up to 5,000 tonnes of insect protein and 2,000 tonnes of insect oil a year, produced by black soldier fly larvae fed on side streams from the food industry. The company says the facility was delivered on schedule and within its €15 million capex budget.
The plant was fitted into a former newspaper printing facility and built in roughly nine months, which chief executive and co-founder Jarna Hyvönen estimates saved at least a year against a new build. It runs on electricity alone with four people per shift, and represents about a thousandfold scale-up from the demonstration line Volare operated for more than four years. Measured against competing insect protein producers, the company claims four to ten times lower capex, around half the headcount and 30 per cent less energy in end-product processing, with protein meal digestibility above 90 per cent. Tuure Parviainen is co-founder and chief strategy officer, Matti Tähtinen co-founder and chief technology officer.
A significant share of Volare 01's capacity is already contracted. Offtake agreements are in place with the aquafeed company Skretting and with a global chemical company that has not been named. Volare has sold protein commercially since 2022, into dog treats with Alvar Pet, cat food under the Vafo Group brand Dagsmark, rainbow trout feed with Alltech Fennoaqua, and organic poultry feed. Alongside the opening, the company raised €7.1 million through the Finnish investment platform Springvest, from new and existing investors including Maki.vc. The money funds the ramp-up of the first plant and preparation of the next, which is planned at roughly five times Volare 01's protein capacity. No site or date has been given for it.
Two constraints sit around the business. EU rules still bar insect farms from feeding post-consumer food waste and most animal by-products, which keeps the cheapest feedstocks off the table. Hyvönen told AgFunderNews that she expects the rules to loosen over time but that the business model does not depend on that happening. The second constraint is the sector's record. Tech.eu sets Volare against a run of failures: Ÿnsect in France, which raised more than €600 million before entering judicial liquidation in 2025, ENORM in Denmark, which raised €50 million and was declared bankrupt in October 2025, and FarmInsect in Germany, which raised around €16.2 million in equity and public funding before going insolvent in 2026 and ceasing operations.
Why it matters for AgTech founders: the interesting number here is not the capacity, it is the €15 million. Insect protein did not fail on the science, it failed on capital intensity, and the companies that raised the most money built the most expensive plants. Volare's answer was to treat the factory itself as the product, which meant an existing industrial shell, nine months of fit-out, an all-electric process and four operators a shift. Three things are worth copying. First, a brownfield shell converts capex into schedule, and in a feed market where the comparator is commodity fishmeal, schedule decides whether a first plant ever reaches positive contribution. Second, contracted offtake before commissioning, here with Skretting and a chemical buyer, is what turns a scale-up into a financeable asset, and it also tells you which price point the plant was designed around. Third, €7.1 million is sized for a ramp-up rather than a moonshot, and it came through a retail investment platform rather than a large venture round. The signal for anyone building in biomanufacturing is that once unit economics hold at one site, the next raise is a project finance conversation, and the diligence question shifts from technology risk to cost per tonne against the incumbent commodity.
Volare opens its first industrial insect protein factory in Pori, on schedule and on budget
The Finnish company completed Volare 01 inside a €15 million capex budget and secured a further €7.1 million through Springvest, with a significant share of the plant's 5,000 tonne protein capacity already sold.
Volare, a Finnish insect protein company founded in 2021 on technology out of the VTT Technical Research Centre of Finland, has completed Volare 01, its first industrial-scale factory, in Pori. Tech.eu reported the completion on 26 October 2026. The 10,000 square metre plant is designed for up to 5,000 tonnes of insect protein and 2,000 tonnes of insect oil a year, produced by black soldier fly larvae fed on side streams from the food industry. The company says the facility was delivered on schedule and within its €15 million capex budget.
The plant was fitted into a former newspaper printing facility and built in roughly nine months, which chief executive and co-founder Jarna Hyvönen estimates saved at least a year against a new build. It runs on electricity alone with four people per shift, and represents about a thousandfold scale-up from the demonstration line Volare operated for more than four years. Measured against competing insect protein producers, the company claims four to ten times lower capex, around half the headcount and 30 per cent less energy in end-product processing, with protein meal digestibility above 90 per cent. Tuure Parviainen is co-founder and chief strategy officer, Matti Tähtinen co-founder and chief technology officer.
A significant share of Volare 01's capacity is already contracted. Offtake agreements are in place with the aquafeed company Skretting and with a global chemical company that has not been named. Volare has sold protein commercially since 2022, into dog treats with Alvar Pet, cat food under the Vafo Group brand Dagsmark, rainbow trout feed with Alltech Fennoaqua, and organic poultry feed. Alongside the opening, the company raised €7.1 million through the Finnish investment platform Springvest, from new and existing investors including Maki.vc. The money funds the ramp-up of the first plant and preparation of the next, which is planned at roughly five times Volare 01's protein capacity. No site or date has been given for it.
Two constraints sit around the business. EU rules still bar insect farms from feeding post-consumer food waste and most animal by-products, which keeps the cheapest feedstocks off the table. Hyvönen told AgFunderNews that she expects the rules to loosen over time but that the business model does not depend on that happening. The second constraint is the sector's record. Tech.eu sets Volare against a run of failures: Ÿnsect in France, which raised more than €600 million before entering judicial liquidation in 2025, ENORM in Denmark, which raised €50 million and was declared bankrupt in October 2025, and FarmInsect in Germany, which raised around €16.2 million in equity and public funding before going insolvent in 2026 and ceasing operations.
Why it matters for AgTech founders: the interesting number here is not the capacity, it is the €15 million. Insect protein did not fail on the science, it failed on capital intensity, and the companies that raised the most money built the most expensive plants. Volare's answer was to treat the factory itself as the product, which meant an existing industrial shell, nine months of fit-out, an all-electric process and four operators a shift. Three things are worth copying. First, a brownfield shell converts capex into schedule, and in a feed market where the comparator is commodity fishmeal, schedule decides whether a first plant ever reaches positive contribution. Second, contracted offtake before commissioning, here with Skretting and a chemical buyer, is what turns a scale-up into a financeable asset, and it also tells you which price point the plant was designed around. Third, €7.1 million is sized for a ramp-up rather than a moonshot, and it came through a retail investment platform rather than a large venture round. The signal for anyone building in biomanufacturing is that once unit economics hold at one site, the next raise is a project finance conversation, and the diligence question shifts from technology risk to cost per tonne against the incumbent commodity.